AIM ImmunoTech Inc. announced the completion of enrollment in the company's Phase 2 study evaluating Ampligen(R) as a potential therapeutic for people with post-COVID conditions ("AMP-518"). The study has met the planned enrollment of 80 AMP-518 subjects ages 18 to 60 years who have been randomized 1:1 to receive twice-weekly intravenous infusions of Ampligen or placebo for 12 weeks, with a follow-up phase of two weeks. The ompany expects to complete dosing of the last study patient in Fourth Quarter 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3727 USD | -4.44% |
|
-9.19% | -15.28% |
06-05 | Transcript : AIM ImmunoTech Inc. - Special Call | |
05-16 | Transcript : AIM ImmunoTech Inc., Q1 2024 Earnings Call, May 16, 2024 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.28% | 21.29M | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- AIM Stock
- News AIM ImmunoTech Inc.
- AIM Immunotech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen(R) for the Treatment of Post-Covid Conditions